Home > Annual Financials > SUVEN PHARMACEUTICALS

SUVEN PHARMACEUTICALS Financial Statement Analysis
[BOM: 543064|NSE : SUVENPHAR]

The Revenues of SUVEN PHARMACEUTICALS have increased by 30.75% YoY .
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -9.37 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

SUVEN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 543064|NSE : SUVENPHAR]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹1,320 Cr₹1,010 Cr₹834 Cr₹378 Cr₹378 Cr
Expenses ₹739 Cr₹567 Cr₹449 Cr₹206 Cr₹206 Cr
Operating Profit (Excl OI) ₹582 Cr₹443 Cr₹385 Cr₹172 Cr₹172 Cr
Other Income ₹92 Cr₹14 Cr₹18 Cr₹0.60 Cr₹0.60 Cr
Interest ₹8.53 Cr₹12 Cr₹23 Cr₹2.79 Cr₹2.79 Cr
Depreciation ₹39 Cr₹32 Cr₹24 Cr₹11 Cr₹11 Cr
Profit Before Tax ₹668 Cr₹414 Cr₹356 Cr₹158 Cr₹158 Cr
Profit After Tax ₹454 Cr₹309 Cr₹269 Cr₹109 Cr₹109 Cr
Consolidated Net Profit ₹454 Cr₹362 Cr₹317 Cr₹109 Cr₹109 Cr
Earnings Per Share (Rs)₹16.16₹17.83₹14.23₹24.91₹0.00
PAT Margin (%)30.6634.3530.5632.2428.92
ROE(%)25.2133.5230.4737.8018.92
ROCE(%)33.4145.9236.1944.5523.87
Total Debt/Equity(x)0.040.060.120.220.14

Key Financials

Market Cap : ₹ 17,226.2 Cr
Revenue (TTM) : ₹ 1,167.8 Cr
Net Profit(TTM) : ₹ 370.9 Cr
EPS (TTM) : ₹ 14.6
P/E (TTM) : 46.4

Industry Peers & Returns1W1M1Y
SUVEN PHARMACEUTICALS 5.1% -3.2% 38.4%
SUN PHARMACEUTICAL INDUSTRIES 3% 2.3% 68.2%
CIPLA 2.5% 0.4% 71.7%
DR REDDYS LABORATORIES -0.2% -4.9% 40.3%
ZYDUS LIFESCIENCES 5% 10.4% 109.1%
DIVIS LABORATORIES -1.6% -7% 23.8%
MANKIND PHARMA NA NA NA
TORRENT PHARMACEUTICALS 2.9% -2.2% 69%
LUPIN 2.8% 0% 147.8%


SUVEN PHARMACEUTICALS Revenues
[BOM: 543064|NSE : SUVENPHAR]

Y-o-Y

30.75 %

5 Yr CAGR

36.72 %

Years Revenues % Change
Mar2023 ₹1,320 Cr
30.75
Mar2022 ₹1,010 Cr
21.10
Mar2021 ₹834 Cr
120.68
Mar2020 ₹378 Cr
0.00
Mar2019 ₹378 Cr -


SUVEN PHARMACEUTICALS Operating Profit
[BOM: 543064|NSE : SUVENPHAR]

Y-o-Y

31.31 %

5 Yr CAGR

35.70 %

Years Operating Profit % Change
Mar2023 ₹582 Cr
31.31
Mar2022 ₹443 Cr
15.14
Mar2021 ₹385 Cr
124.28
Mar2020 ₹172 Cr
0.00
Mar2019 ₹172 Cr -

Operating Margins
Y-o-Y

0.43 %

5 Yr CAGR

-0.75 %

Years Operating Margin% % Change
Mar2023 44.06%
0.43
Mar2022 43.87%
-4.94
Mar2021 46.15%
1.65
Mar2020 45.4%
0.00
Mar2019 45.4% -

SUVEN PHARMACEUTICALS Profit After Tax
[BOM: 543064|NSE : SUVENPHAR]

Y-o-Y

25.24 %

5 Yr CAGR

42.75 %

Years Profit After Tax % Change
Mar2023 ₹454 Cr
25.24
Mar2022 ₹362 Cr
14.30
Mar2021 ₹317 Cr
190.10
Mar2020 ₹109 Cr
0.00
Mar2019 ₹109 Cr -

PAT Margins
Y-o-Y

-10.74 %

5 Yr CAGR

1.47 %

Years PAT Margin(%) % Change
Mar2023 30.66 %
-10.74
Mar2022 34.35 %
12.40
Mar2021 30.56 %
-5.21
Mar2020 32.24 %
11.48
Mar2019 28.92 % -

SUVEN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 543064|NSE : SUVENPHAR]

Y-o-Y

-9.37 %

5 Yr CAGR

0

Years EPS % Change
Mar2023 ₹16
-9.37
Mar2022 ₹18
25.30
Mar2021 ₹14
-42.87
Mar2020 ₹25
0
Mar2019 ₹0.00 -

SUVEN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 543064|NSE : SUVENPHAR]

Y-o-Y

-27.24 %

5 Yr CAGR

8.77 %

Years ROCE % Change
Mar2023 33.41%
-27.24
Mar2022 45.92%
26.89
Mar2021 36.19%
-18.77
Mar2020 44.55%
86.64
Mar2019 23.87% -

SUVEN PHARMACEUTICALS Share Price vs Sensex

Current Share Price : ₹676.6
Current MarketCap: ₹ 17,226.2 Cr
Updated EOD on :Mar 28,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
SUVEN PHARMACEUTICALS

5.1%

-3.2%

38.4%

SENSEX

-0.4%

-0.9%

25.8%

SUVEN PHARMACEUTICALS related INDICES

BSE Indices1W1M1Y
S&P BSE 400 MIDSMALLCAP 2.1% -3.5% 55.9%
S&P BSE 250 SMALLCAP 2% -5.8% 56.3%
S&P BSE MIDSMALLCAP 1.9% -4.4% 61.2%
S&P BSE SMALL CAP 1.8% -6.7% 58.8%
S&P BSE HEALTHCARE 1% -3.2% 60.6%
NSE Indices1W1M1Y
NIFTY MID SMALL400 2.4% -3.7% 58.5%
NIFTY SMALLCAP250 2.1% -6.1% 61.4%
NIFTY500 MULTICAP 50:25:25 1.3% -2.4% 46.5%
NIFTY 500 0.8% -1.4% 39.7%

You may also like the below Video Courses


FAQ about SUVEN PHARMACEUTICALS Financials


How the annual revenues of SUVEN PHARMACEUTICALS have changed ?

The Revenues of SUVEN PHARMACEUTICALS have increased by 30.75% YoY .

How the Earnings per Share (EPS) of SUVEN PHARMACEUTICALS have changed?

The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -9.37 % YoY .